A 40-week open, flexible dose, extension study of bifeprunox in patients with schizophrenia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000707-18-IT

Enrollment

480

Registered

2005-06-22

Start date

2004-09-28

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long-term schizophrenia treatment MedDRA version: 6.1 Level: PT Classification code 10039626

Interventions

Product Name: Bifeprunox mesylate Pharmaceutical Form: CAS Number: 350992-13-1 Current Sponsor code: Lu 02-754-X Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026